HR Execs on the Move

Zentalis

www.zentalis.com

 
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor, ZN-d5, a BCL-2 inhibitor and ZN-e4, an EGFR inhibitor. Zentalis has operations in both New York and San Diego.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.zentalis.com
  • 530 Seventh Avenue Suite 2201
    New York, NY USA 10018
  • Phone: 212.433.3791

Executives

Name Title Contact Details
Chad Hopkins
 Director, Preclinical Research and Development Profile
Sheena Delgado
 Associate Director Human Resources Profile
Debby Silott
 Senior Director, Human Resources Profile

Similar Companies

Octapharma USA

Octapharma is committed to promoting excellence in patient care and providing valuable information to the medical and patient community. This will help to better manage the treatment of disease and to improve patient safety and population health

FIRSTMED HOLDING CORP

FIRSTMED HOLDING CORP is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Agensys

Agensys is a Santa Monica, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

ChemNavigator

At ChemNavigator we help research organizations identify and procure the chemistry they need for drug discovery and agrochemical research. We serve researchers in medicinal, computational, and synthetic chemistry as well as chemical procurement

Ocera Therapeutics

Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate). OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease.